Carl Zeiss Meditec AG (XSWX:AFX) EPS without NRI: CHF1.29 (TTM As of Dec. 2025)


XSWX:AFX Carl Zeiss Meditec AG XSWX:AFX
80 GF Score
Price CHF25.10
GF Value CHF69.46
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Carl Zeiss Meditec AG EPS without NRI?

Carl Zeiss Meditec AG XSWX:AFX 80 EPS without NRI is CHF1.29 as of Dec. 2025. GuruFocus rates XSWX:AFX with a GF Score™ of 80/100 and a GF Value™ of CHF69.46 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 666 Medical Devices & Instruments companies, Carl Zeiss Meditec AG ranks worse than 84.98% on this metric.

Carl Zeiss Meditec AG's earnings per share without non-recurring items for the three months ended in Dec. 2025 was CHF-0.06. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was CHF1.29.

During the past 12 months, Carl Zeiss Meditec AG's average earnings per share (NRI) Growth Rate was -22.60% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was -23.30% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -2.30% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 7.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Carl Zeiss Meditec AG's EPS without NRI or its related term are showing as below:

XSWX:AFX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -23.3   Med: 7.2   Max: 27
Current: -23.3

During the past 13 years, Carl Zeiss Meditec AG's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 27.00% per year. The lowest was -23.30% per year. And the median was 7.20% per year.

XSWX:AFX's 3-Year EPS without NRI Growth Rate is ranked worse than
84.98% of 666 companies
in the Medical Devices & Instruments industry
Industry Median: 8.15 vs XSWX:AFX: -23.30

Carl Zeiss Meditec AG's EPS (Diluted) for the three months ended in Dec. 2025 was CHF-0.06. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was CHF1.29.

Carl Zeiss Meditec AG's EPS (Basic) for the three months ended in Dec. 2025 was CHF-0.06. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was CHF1.29.


Carl Zeiss Meditec AG  (XSWX:AFX) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Carl Zeiss Meditec AG EPS without NRI Related Terms


Carl Zeiss Meditec AG EPS without NRI Historical Data

* Premium members only.

The historical data trend for Carl Zeiss Meditec AG's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carl Zeiss Meditec AG EPS without NRI Chart

Carl Zeiss Meditec AG Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.87 3.17 2.69 1.76 1.39

Carl Zeiss Meditec AG Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.50 0.30 0.55 -0.06

XSWX:AFX vs ISRG, BDX, MDLN: EPS without NRI Comparison

For the Medical Instruments & Supplies subindustry, Carl Zeiss Meditec AG's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Carl Zeiss Meditec AG PE Ratio without NRI vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Carl Zeiss Meditec AG's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Carl Zeiss Meditec AG's PE Ratio without NRI falls into.


XSWX:AFX
80GF Score
Carl Zeiss Meditec AG XSWX:AFX
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Carl Zeiss Meditec AG EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF1.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of CHF1.29 mean?
Carl Zeiss Meditec AG (XSWX:AFX) has a EPS without NRI of CHF1.29 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Carl Zeiss Meditec AG and its competitors. According to the industry distribution chart, Carl Zeiss Meditec AG ranks #566 out of 666 companies in the Medical Devices & Instruments industry, placing it in the top 85%.
Is Carl Zeiss Meditec AG's EPS without NRI too high?
Carl Zeiss Meditec AG's current EPS without NRI is CHF1.29. Based on the distribution chart, Carl Zeiss Meditec AG ranks #566 out of 666 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Carl Zeiss Meditec AG has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Carl Zeiss Meditec AG's EPS without NRI compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Carl Zeiss Meditec AG ranks #566 out of 666 companies for EPS without NRI. This places Carl Zeiss Meditec AG in the lower half of its industry. The industry median EPS without NRI is 8.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Devices & Instruments company?
The median EPS without NRI among Medical Devices & Instruments companies is 8.15, based on 666 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Carl Zeiss Meditec AG and its competitors. For the Medical Devices & Instruments industry, the median EPS without NRI is 8.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carl Zeiss Meditec AG's current EPS without NRI is CHF1.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carl Zeiss Meditec AG stock overvalued right now?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG (XSWX:AFX) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF69.46, compared to a current price of CHF25.10 — trading 63.9% below its estimated fair value. The current EPS without NRI is CHF1.29. Carl Zeiss Meditec AG's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Carl Zeiss Meditec AG (XSWX:AFX), the current EPS without NRI is CHF1.29 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carl Zeiss Meditec AG (XSWX:AFX) Overvalued in 2026?

Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued. The current stock price of CHF25.10 is trading 63.9% below its estimated GF Value™ of CHF69.46. GuruFocus considers Carl Zeiss Meditec AG to be Significantly Undervalued.

Key valuation signals for XSWX:AFX:

  • EPS without NRI: CHF1.29
  • GF Value™: CHF69.46 vs. price of CHF25.10 (63.9% below fair value)
  • GF Score™: 80/100 with 4 warning signs

No single metric tells the full story. See the XSWX:AFX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Carl Zeiss Meditec AG Business Description

Address Goschwitzer Strasse 51-52, Jena, TH, DEU, 07745
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
80GF Score

Get the complete analysis for XSWX:AFX

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF25.10
Price
CHF69.46
GF Value